Medtech and pharmaceutical companies have made several important strides over the past year when it comes to improving diabetes treatment. Multiple treatments and technologies have cleared regulatory hurdles and are now hitting the market and making the process of living with diabetes that much more manageable. Several different styles of therapy and devices have come […]
Senseonics launches Eversense CGM System with non-adjunctive claim
Senseonics (NYSE:SENS) this week said it launched its Eversense continuous glucose monitoring system with its mobile app that can dose based on the system’s readings. The Eversense System is a long-term, implantable CGM sensor that features a transmitter that sends discreet vibrations to alert users of low and high glucose levels. The system with the CGM […]
Senseonics lists $200 million offering
Senseonics (NYSE:SENS) posted a $200 million offering of common stock, preferred stock, debt securities and/or warrants, including an agreement for Jefferies to handle $50 million. The total offering includes the company’s common stock, which was trading at $1.03 per share in midday trading today. Senseonics — which makes glucose monitoring products — said the securities in […]
Senseonics touts Humana reimbursement nod for Eversense CGM
Senseonics (NYSE:SENS) said yesterday that Humana is now providing coverage for its Eversense continuous glucose monitoring system and insertion procedure. Humana is the fifth-largest health insurer in the U.S. with 17 million patients in 50 states, Washington, D.C. and Puerto Rico, according to a news release. Its coverage policy with Senseonics makes patients with Type 1 […]
Senseonics touts Eversense reimbursement win
Senseonics (NYSE:SENS) said this week that Health Care Service Corporation – Blue Cross Blue Shield is providing coverage for the Eversense continuous glucose monitoring system, effective as of yesterday. HCSC – Blue Cross Blue Shield is the fourth-largest health insurer in the U.S. and serves more than 16 million members, according to a news release. Last […]
Senseonics touts BCBS reimbursement wins
Senseonics (NYSE:SENS) said today that Blue Cross Blue Shield of Massachusetts and Idaho now provide coverage for the implantable Eversense continuous glucose monitor. The company’s Eversense device includes a fluorescence-based sensor, a mobile app and a transmitter. Senseonics’ touts its system as being the first with a long-term, implantable CGM sensor, as well as the first […]
Senseonics touts long-term safety data on home-use Eversense
Senseonics (NYSE:SENS) yesterday touted real-world data it said demonstrated the safety and lack of adverse events with its Eversense continuous glucose monitoring system for people with diabetes. Eversense is a long-term, implantable GCM sensor with a transmitter that sends discreet vibrations to alert users of low or high glucose. The device can be removed, recharged and […]
Senseonics touts real-world CGM data
Senseonics (NYSE:SENS) announced yesterday that real-world data from its Eversense continuous glucose monitoring system reflected strong performance and safety. The data, published in Diabetes Technology and Therapeutics, included the first 205 U.S. patients to use Germantown, Md.-based Senseonics’ Eversense system over a 90-day wear period. Zero device or procedure-related adverse events were reported with the […]
Senseonics prices $107m worth of stock, debt offerings
Senseonics (NYSE:SENS) today priced stock and debt offerings worth a total of at least $107 million. Germantown, Md.-based Senseonics, which developed the Eversense implantable CGM, announced the offerings yesterday. Get the full story at our sister site, Drug Delivery Business News
Senseonics slides on stock, debt offerings, Q2 prelims
Senseonics (NYSE:SENS) shares are off nearly -7% today after the continuous glucose monitor maker revealed plans for a stock and debt offerings and released its preliminary second-quarter sales numbers. Germantown, Md.-based Senseonics, which developed the Eversense implantable CGM, said it plans to float $25 million in stock (plus a 30-day, $3.8 million underwriters option) and $80 […]
Beta Bionics touts results of bionic pancreas system study
Beta Bionics’ iLet bionic pancreas system significantly increased the percentage of time that adults with Type 1 diabetes spent with glucose levels between 70–180 mg/dl when compared to usual care therapy, according to a new study. The study’s results also suggest that the iLet, using either the Senseonics (NYSE:SENS)Eversense continuous glucose monitoring system (CGM) or […]
- 1
- 2
- 3
- …
- 6
- Next Page »
MassDevice Network
@MassDevice
LinkedIn
YouTube